Véronique D'Hondt

11PUBLICATIONS
101CO-AUTHORS
Predictive and prognostic markersMolecular targetsMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Dec 03, 2025
18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

M Chanchou, M A Mouret-Reynier, I Molnar

|Sep 04, 2025
Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.

Barbara Pistilli, Fernanda Mosele, Noemie Corcos

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Jul 09, 2025
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning.

Sarah Dandou, Kriti Amin, Véronique D'Hondt

|Mar 07, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Angeline Ginzac, Ioana Molnar, Xavier Durando

Pageof 2

Frequent Collaborators

3 joint publications

Manuel Rodrigues

2 joint publications

Ioana Molnar

2 joint publications

Coriolan Lebreton

2 joint publications

Florence Joly